Kazia Therapeutics Limited received a letter on May 22, 2024 from Nasdaq notifying the Company that, while the Company has not regained compliance with the Minimum Bid Price Requirement, Nasdaq has determined that the Company is eligible for an additional 180 calendar day period, or until November 18, 2024, to regain compliance with the Minimum Bid Price Requirement.
May 23, 2024
· 5 min read